HomeCompareCTBO vs SBUX

CTBO vs SBUX: Dividend Comparison 2026

CTBO yields 198.02% · SBUX yields 2.84%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 CTBO wins by $112.53M in total portfolio value
10 years
CTBO
CTBO
● Live price
198.02%
Share price
$1.01
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$112.70M
Annual income
$56,534,499.65
Full CTBO calculator →
SBUX
SBUX
● Live price
2.84%
Share price
$86.72
Annual div
$2.46
5Y div CAGR
48.3%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$167.0K
Annual income
$71,136.45
Full SBUX calculator →

Portfolio growth — CTBO vs SBUX

📍 CTBO pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodCTBOSBUX
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, CTBO + SBUX cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
CTBO pays
SBUX pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CTBO
Annual income on $10K today (after 15% tax)
$16,831.68/yr
After 10yr DRIP, annual income (after tax)
$48,054,324.70/yr
SBUX
Annual income on $10K today (after 15% tax)
$241.12/yr
After 10yr DRIP, annual income (after tax)
$60,465.98/yr
At 15% tax rate, CTBO beats the other by $47,993,858.72/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CTBO + SBUX for your $10,000?

CTBO: 50%SBUX: 50%
100% SBUX50/50100% CTBO
Portfolio after 10yr
$56.43M
Annual income
$28,302,818.05/yr
Blended yield
50.15%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on SBUX right now

CTBO
No analyst data
SBUX
Analyst Ratings
28
Buy
27
Hold
3
Sell
Consensus: Buy
Price Target
$104.00
+19.9% upside vs current
Range: $90.00 — $120.00
Altman Z
2.6
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CTBO buys
0
SBUX buys
0
No recent congressional trades found for CTBO or SBUX in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricCTBOSBUX
Forward yield198.02%2.84%
Annual dividend / share$2.00$2.46
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%48.3%
Portfolio after 10y$112.70M$167.0K
Annual income after 10y$56,534,499.65$71,136.45
Total dividends collected$106.15M$136.4K
Payment frequencyquarterlyquarterly
SectorStockConsumer Discretionary

Year-by-year: CTBO vs SBUX ($10,000, DRIP)

YearCTBO PortfolioCTBO Income/yrSBUX PortfolioSBUX Income/yrGap
1← crossover$30,502$19,801.98$11,121$420.68+$19.4KCTBO
2$89,086$56,448.56$12,548$648.40+$76.5KCTBO
3$249,403$154,080.96$14,440$1,013.98+$235.0KCTBO
4$670,003$403,142.26$17,068$1,617.30+$652.9KCTBO
5$1,729,066$1,012,162.66$20,912$2,649.52+$1.71MCTBO
6$4,291,289$2,441,188.37$26,875$4,499.29+$4.26MCTBO
7$10,253,990$5,662,310.92$36,771$8,014.12+$10.22MCTBO
8$23,616,660$12,644,890.45$54,542$15,197.11+$23.56MCTBO
9$52,487,868$27,218,041.68$89,602$31,242.49+$52.40MCTBO
10$112,696,518$56,534,499.65$167,011$71,136.45+$112.53MCTBO

CTBO vs SBUX: Complete Analysis 2026

CTBOStock

Cantabio Pharmaceuticals, Inc., a preclinical stage biotechnology company, focuses on the research, development, and commercialization of novel therapies for Parkinson's disease (PD), Alzheimer's disease (AD), and other related diseases. Its lead programs include CB101, a DJ-1 targeting small molecule pharmacological chaperone for use in the treatment of PD; CB201, a CNS penetrant engineered DJ-1 protein for use in the treatment of PD; CB301, a Tau protein targeting small molecule pharmacological chaperone for use in the treatment of AD; and CB401, an Aß targeting small molecule pharmacological chaperone for use in the treatment of AD. The company has a collaboration agreement with Luxembourg Institute of Health to research the therapeutic targeting of the DJ-1 - protein to treat immune associated diseases. The company was founded in 2009 and is based in Palo Alto, California.

Full CTBO Calculator →

SBUXConsumer Discretionary

Starbucks Corporation, together with its subsidiaries, operates as a roaster, marketer, and retailer of specialty coffee worldwide. The company operates through three segments: North America, International, and Channel Development. Its stores offer coffee and tea beverages, roasted whole beans and ground coffees, single serve products, and ready-to-drink beverages; and various food products, such as pastries, breakfast sandwiches, and lunch items. The company also licenses its trademarks through licensed stores, and grocery and foodservice accounts. The company offers its products under the Starbucks, Teavana, Seattle's Best Coffee, Evolution Fresh, Ethos, Starbucks Reserve, and Princi brands. As of October 3, 2021, it operated 16,826 company-operated and licensed stores in North America; and 17,007 company-operated and licensed stores internationally. The company was founded in 1971 and is based in Seattle, Washington.

Full SBUX Calculator →
📬

Get this CTBO vs SBUX comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CTBO vs SCHDCTBO vs JEPICTBO vs OCTBO vs KOCTBO vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.